Pluvia is a pioneering brand dedicated to developing innovative therapies for patients suffering from rare genetic disorders. As a spin-out from the University of Bergen in Norway, Pluvia is built on a foundation of groundbreaking research on protein structure and misfolding. Their primary focus is on developing small molecule pharmacological chaperones, which have the potential to stabilize and correct the misfolding of proteins associated with selected loss-of-function diseases.

One of Pluvia's leading projects is centered around phenylketonuria (PKU), a rare genetic disorder caused by mutations in the enzyme phenylalanine hydroxylase. This disorder leads to the defective degradation and accumulation of the amino acid phenylalanine, resulting in toxicity to the brain. Pluvia aims to develop a proprietary technology platform to target multiple rare diseases caused by protein misfolding.

Pluvia's team consists of highly qualified professionals with expertise in various fields, including biochemistry, drug development, and cellular biology. They are driven by a burning ambition to make a difference in the lives of vulnerable patient populations. Supported by a strong base of Norwegian investors, Pluvia is committed to providing hope and improved quality of life for individuals affected by rare genetic disorders